本帖最后由 老马 于 2012-1-13 21:20 编辑 5 n. Z! G+ |( r: z# y+ R
c1 d, {5 d2 }; w0 d6 z5 {爱必妥和阿瓦斯丁的比较) n, K# y h8 j' t9 @+ d
0 x- w" G% L2 b: F3 J
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
- e- D) ?8 B' ?( Z; Z
, t7 A5 ?5 S) T G/ \
F8 F9 y/ N1 @5 G+ h
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
& I4 D$ s! j; J* Y$ I. [==================================================8 A, J/ K- a2 j2 E3 i
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)% j. J' k1 r% C# ^0 V& E6 J3 Z. c. K' z
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 a/ M) _( S9 Y8 LResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
5 m6 P. X8 U0 O
|